BioShield Technologies, has considerably reduced its overhead and operating expenses which will allow the firm to concentrate on its core business of antiviral and antimicrobial research for the many uses and applications in which contaminants are a tremendous and ever growing world wide problem.
Bioshield also announced in a media statement that it is currently updating its Web site and adding a special section to keep shareholders and the investment community informed on a weekly basis with as many details as possible regarding the firm’s progress.
